⌘K
t
Surgical Innovations Group plc announced on 28 November 2025 the establishment of a new Long Term Incentive Plan (2025 LTIP) for certain executive directors and employees. Under this plan, the Company awarded nil cost share options on 27 November 2025 over a total of 16,086,955 ordinary shares. This included 9,130,434 options to CEO David Marsh and 6,956,521 options to CFO Brent Greetham, exercisable at nil cost and subject to vesting conditions over three years ending on 26 November 2028.
| Date | 28 Nov 2025 |
| Time | 07:00:12 |
| Category | Director/PDMR dealings |
| ID | 3418J |
Surgical Innovations Group plc
("Surgical Innovations", the "Company", or the "Group")
Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces the establishment of a new Long Term Incentive Plan ("2025 LTIP") for certain executive directors and employees in order to incentivise them in a manner that aligns with the interests of the Company's shareholders.
New LTIP
Under the terms of the 2025 LTIP, the Company has awarded nil cost share options (the "Options") over a total of 16,086,955 ordinary shares of 1 pence each in the Company ("Ordinary Shares") including to certain persons discharging managerial responsibilities ("PDMRs") as set out below.
The Options may be exercised at nil cost and are subject to performance criteria relating to revenue growth, EBIT growth and total shareholder returns alongside continuous employment with the Company for a period of three years ending on 26th November 2028.
The following PDMRs have been awarded Options:
|
PDMRs |
Role |
No. of Options awarded |
Total Options held post award |
|
David Marsh |
Chief Executive Officer |
9,130,434 |
9,130,434 |
|
Brent Greetham |
Chief Financial Officer |
6,956,521 |
6,956,521 |
In developing the 2025 LTIP and determining the award of Options, the Remuneration Committee engaged in consultation with the Company's largest shareholder.
|
Surgical Innovations Group plc |
|||
|
David Marsh, CEO |
Tel: 0113 230 7597 |
||
|
Brent Greetham, CFO |
|
||
|
|
|
||
|
Singer Capital Markets (Nominated Adviser & Broker) |
Tel: 020 7496 3000 |
||
|
Alex Bond / Oliver Platts |
|
||
|
|
|
||
|
Walbrook PR (Financial PR & Investor Relations) |
Tel: 020 7933 8780 or si@walbrookpr.com |
||
|
Paul McManus / Lianne Applegarth |
Mob: 07980 541 893 / 07584 391 303 |
||
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.
We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs, the Company's Reposable portfolio enables healthcare providers to reduce both plastic waste and their CO2 footprint as they strive for net zero.
Further information
Further details of the Group's businesses and products are available on the following websites:
To receive regular updates by email, please contact si@walbrookpr.com
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||
|
a) |
Name |
1. David Marsh 2. Brent Greetham |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
1. Chief Executive Officer 2. Chief Financial Officer |
||||
|
b) |
Initial notification/ Amendment |
Initial Notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Surgical Innovations Group plc |
||||
|
b) |
LEI |
2138004GHGUH3HUZE156 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares of 1p
GB0004016704
|
||||
|
b) |
Nature of the transactions |
Grant of options |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information - Aggregated volume - Price |
N/A N/A
|
||||
|
e) |
Date of the transaction |
27 November 2025 |
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||